Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Madrigal Pharmaceuticals (MDGL) Return on Capital Employed (2019 - 2025)

Historic Return on Capital Employed for Madrigal Pharmaceuticals (MDGL) over the last 13 years, with Q3 2025 value amounting to 0.39%.

  • Madrigal Pharmaceuticals' Return on Capital Employed rose 2200.0% to 0.39% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.39%, marking a year-over-year increase of 2200.0%. This contributed to the annual value of 0.74% for FY2024, which is 2500.0% up from last year.
  • Per Madrigal Pharmaceuticals' latest filing, its Return on Capital Employed stood at 0.39% for Q3 2025, which was up 2200.0% from 0.38% recorded in Q2 2025.
  • Madrigal Pharmaceuticals' Return on Capital Employed's 5-year high stood at 0.38% during Q2 2025, with a 5-year trough of 3.08% in Q3 2022.
  • Moreover, its 5-year median value for Return on Capital Employed was 0.96% (2021), whereas its average is 1.15%.
  • Its Return on Capital Employed has fluctuated over the past 5 years, first plummeted by -21200bps in 2022, then skyrocketed by 14400bps in 2024.
  • Over the past 5 years, Madrigal Pharmaceuticals' Return on Capital Employed (Quarter) stood at 1.14% in 2021, then tumbled by -78bps to 2.03% in 2022, then soared by 42bps to 1.19% in 2023, then soared by 53bps to 0.56% in 2024, then skyrocketed by 31bps to 0.39% in 2025.
  • Its Return on Capital Employed was 0.39% in Q3 2025, compared to 0.38% in Q2 2025 and 0.5% in Q1 2025.